Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Management of Neonates Born to Women With Graves’ Disease: A Cohort Study
source: European Journal of Endocrinology / European Federation of Endocrine Societies
year: 2014
authors: Besançon A, Beltrand J, Le Gac I, Luton D, Polak M
summary/abstract:Objective:
Hyperthyroidism in neonates born to mothers with Graves’ disease (GD) can be associated with significant morbidity and mortality, but is still overlooked by clinicians. Management of neonatal hyperthyroidism would be improved by a better understanding of the predictive factors involved. The aim of this study was to evaluate the course of thyroid function and clinical outcomes during the first postnatal month in babies born to mothers with GD.
Design:
Prospective observational study.
Methods:
Sixty-eight neonates born to mothers with GD were managed from birth and divided into three groups based on thyrotropin receptor antibody (TRAb) and anti-thyroid drug (ATD) status in the mother: TRAb(-ve)/ATD(-ve), n=27; TRAb(-ve)/ATD(+) (ve), n=8; and TRAb(+ve)/ATD(+ve), n=33. The main outcome measures were clinical examination, thyroid function tests (TSH, free thyroxine (FT4), free triiodothyronine, and TRAb), echocardiography, thyroid ultrasonography, and bone maturation assessment.
Results:
None of the infants born to TRAb(-ve) mothers with GD developed neonatal hyperthyroidism. Of the 33 TRAb(+ve)/ATD(+ve) neonates, 24 (72.7%) had positive TRAb on cord blood assays, and seven of these developed neonatal hyperthyroidism. FT4 elevation between days 3 and 7 but not at birth was predictive of the development of hyperthyroidism.
Conclusions:
TRAb status should be checked in the third trimester in mothers with GD and on cord blood in their neonates; if positive, it indicates a high risk of neonatal hyperthyroidism. FT4 measurement at birth should be repeated between days 3 and 5 (and by day 7 at the latest); rapid FT4 elevation during the first postnatal week is predictive of hyperthyroidism and warrants ATD therapy.
DOI: 10.1530/EJE-13-0994
read more full text
myBinderRelated Content
-
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thy...Background: Thyrotoxicosis has multip...
-
Failure of Radioactive Iodine in the Treatment of HyperthyroidismBackground: Persistent or recurrent hyp...
-
Hyperthyroidism in Children and AdolescentsWhat is the Thyroid Gland? The thyroid ...
-
Treatment Choice, Satisfaction and Quality of Life in Patients With Graves’ DiseaseBackground: Thyrotoxicosis, most often ...
-
Selenium in Graves Hyperthyroidism and OrbitopathyPurpose: To review the in vitro and in ...
-
Lugol’s Solution and Other Iodide Preparations: Perspectives and Research Directions in Graves’ DiseaseLugol's solution and other preparations ...
-
Risk Factors of Hepatic Dysfunction in Patients With Graves’ Hyperthyroidism and the Efficacy of 131iodine Tre...Hepatic dysfunction is often observed in...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google